A Phase I, Open label, Multi-Center Clinical Pharmacological Study of nemolizumab with a Single-dose in Japanese Atopic Dermatitis Patients with moderate to severe pruritus

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225290

Enrollment

Registered

2020-07-22

Start date

2020-09-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis with pruritus who are inadequately controlled by existing therapies

Interventions

investigational material(s) Generic name etc : nemolizumab INN of investigational material : nemolizumab Therapeutic category code : 639 Other biological preparations Dosage and Administration for Inv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Atopic dermatitis with moderate or severe pururitus Patients

Exclusion criteria

Exclusion criteria: -Patients with Hepatitis B virus or hepatitis C virus infection -Patients with Evidence of tuberculosis (TB) infection -Patients with immune deficiency -Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
other Changes in cytokine levels in blood plasma and horny layer	—

Secondary

Measure	Time frame
other Correlation between each evaluation item and cytokine levels in plasma and horny layer	—

Countries

Japan

Contacts

Public ContactClinical Trials Information

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026